PD-1 blockade in advanced NSCLC: a focus on pembrolizumab

Lung cancer is a major worldwide health problem, with an estimated 1.8 million new cases globally in 2012, representing 12.9% of all new cancer cases [1]. There are two main subsets of lung cancer: small cell lung cancer (SCLC) and non–SCLC (NSCLC); NSCLC, as a group of different cancers, comprises approximately 85% of all lung cancers, with an estimated 1.55 million new cases globally in 2012 [1,2]. Lung cancer was responsible for the highest number of cancer deaths worldwide in 2012, estimated at 1.59 million, which represents 19.4% of all cancer deaths.

from # All Medicine by Alexandros G. Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2xix0sM
via IFTTT